Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of AMG 337 in MET amplified gastric/gastroesophageal junction/esophageal adenocarcinoma and other MET amplified solid tumors
2013-001277-24Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of AMG-337 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC) and 1 more (2 cohorts), sponsored by Amgen. Primary endpoint: Objective response rate in MET amplified G/GEJ/E adenocarcinoma (Cohort 1). Started Oct 2013; status: completed.
02
Drugs
AMG-337
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2013-001277-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001277-24.